BS_1BWP5MCT
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 19.68
- os_event
- true
- age_years
- 4.066
- sex
- F
- race
- White
- umap1_2d
- 2.880955683
- umap2_2d
- 0.054068856
- umap1_3d
- -0.916094968
- umap2_3d
- -2.836735544
- umap3_3d
- -0.712816615
- dataset
- Med-CBTN
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650166 | — | — | 0.945 |
| 2 | BS_1BWP5MCT | medulloblastoma | — | 0.929 |
| 3 | BS_D0RDN4K5 | Embryonal tumors | — | 0.921 |
| 4 | SRR1400375 | GTEX | — | 0.908 |
| 5 | SRR1439850 | GTEX | — | 0.908 |
| 6 | BS_77317DY4 | medulloblastoma | — | 0.908 |
| 7 | SRR1433644 | GTEX | — | 0.906 |
| 8 | BS_DBEX7AG2 | Embryonal tumors | — | 0.906 |
| 9 | SRR1474754 | GTEX | — | 0.906 |
| 10 | SRR1467255 | GTEX | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |